Onconova Therapeutics Story Overview

ONTX -- USA Stock  

USD 3.68  0.55  17.57%

Macroaxis does not monitor all media channels or aggregates social signals for Onconova Therapeutics. But even though we do not provide professional-grade financial sentiment analysis on Onconova Therapeutics, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Onconova Therapeutics. Additionally take a look at Your Equity Center.
Conversion by Michael Hoffman of 140449 shares of Onconova Therapeutics
Filed transaction by Onconova Therapeutics Inc director. Derivative codes conversion of derivative security

Onconova Therapeutics Inc insider trading alert for conversion of series c convertible preferred stock by Michael Hoffman, the corporate stakeholder, on March 8, 2018. This event was filed by Onconova Therapeutics Inc with SEC on 2013-08-01. Statement of changes in beneficial ownership - SEC Form 4

Story Momentum

This media report from MacroaxisInsider distributed on March 8, 2018 was a factor to the next trading day price appreciation.The trading delta at closing time against the next closing price was 0.94% . The trading delta at closing time when the story was published against the current closing price is 247.17% .

Similar stores for Onconova Therapeutics

over a week ago at http://www.fairfieldcurrent.com 
Investment Analysts Weekly Ratings Updates for Onconova Therapeutics - Fairfield Current
news
Investment Analysts Weekly Ratings Updates for Onconova Therapeutics Fairfield CurrentSeveral brokerages have updated their recommendations and price targets on shares of Onconova Therapeutics in the last few weeks ...
over a week ago at http://www.streetinsider.com 
Onconova Therapeutics Reports Phase 2 Trial of Oral Rigosertib in Combination with Azacitidine in Myelodysplas...
Street Insider News
Onconova Therapeutics Reports Phase 2 Trial of Oral Rigosertib in Combination with Azacitidine in Myelodysplastic Syndromes StreetInsider.comGet instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Onconova Therapeutics, Inc. ...
over two weeks ago at http://seekingalpha.com 
Onconova Therapeutics The Many Strengths Of INSPIRE - Seeking Alpha
seekingalpha News
Onconova Therapeutics The Many Strengths Of INSPIRE Seeking AlphaOnconovas INSPIRE confirmatory trial is a fascinating construct. Its cutting-edge Adaptive features make it resilient to failure. Valuation of Onconova assumin.
over two weeks ago at http://pressoracle.com 
Renaissance Technologies LLC Buys 672312 Shares of Onconova Therapeutics Inc
news
PressOracleFull coverage
Onconova Therapeutics Releases Earnings Results, Misses Estimates By 0.16 EPSnews
Baseball Daily NewsFull coverage
over a month ago at http://nysedaily.com 
Is this stock is Attractive Onconova Therapeutics
news
NYSE DAILY Full coverage
over a month ago at http://whatsonthorold.com 
Time to Sell Onconova Therapeutics, Inc. After The Completion of This Double Bottom Chart Pattern
news
Thorold NewsFull coverage
over a month ago at http://xnewspress.com 
Onconova Therapeutics Stock Rating Reaffirmed by HC Wainwright
news
XNewsPressFull coverage
over a month ago at http://www.streetinsider.com 
Onconova Therapeutics Secures New Patent from USPTO for Rigosertib
Street Insider News
StreetInsider.comOnconova Therapeutics, Inc. EPS Estimated At -0.05 Thorold NewsFull coverage
over two months ago at http://pressoracle.com 
Onconova Therapeutics Given Buy Rating at HC Wainwright
news
PressOracleFull coverage
over two months ago at http://www.fairfieldcurrent.com 
Onconova Therapeutics Rating Reiterated by HC Wainwright
news
Fairfield CurrentFull coverage
over three months ago at http://thewellesleysnews.com 
Analyst Stock Ratings DelMar Pharmaceuticals, Inc. , Onconova Therapeutics, Inc.
news
Analyst JournalFull coverage
over six months ago at http://alphabetastock.com 
Hot Stocks Highlights Onconova Therapeutics Inc
news
Alpha Beta StockFull coverage

Book Value Per Share

Book Value Per Share Comparative Analysis

  Book Value Per Share 
      Onconova Therapeutics Comparables 
Onconova Therapeutics is currently under evaluation in book value per share category among related companies. Book Value per Share (B/S) is can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing effects of liabilities. In other words a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of liquidation.
Additionally take a look at Your Equity Center. Please also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Search macroaxis.com